NCT04888507View on ClinicalTrials.gov

Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

May 5, 2022

Study Completion Date

May 4, 2023

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

Pozelimab

Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration

DRUG

Cemdisiran

SC administration

Trial Locations (1)

LS9 7TF

Regeneron Study Site, Leeds

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY